Facts
as of Nov 18, 2026
Definium Therapeutics (Formerly MindMed) is forging a new era in psychiatry by harnessing the full therapeutic potential of psychedelic medicine.
It is hiring: 11 open roles, 6 of them posted in the last 30 days.
- Legal name
- Definium Therapeutics Inc.
- Headquarters
- New York, United States
- Employees
- 51-200estimated range
- Listing
- NASDAQ: DFTX
- Open roles
- 11 in 3 citiesAlion job postings
- Register numbers
- NAME definium therapeutics inc
- Website
- definiumtx.com
As of Nov 18, 2026, Alion lists 11 open roles at Definium Therapeutics. Definium Therapeutics is headquartered in New York, United States. The median pay stated in its open roles is $215k, across 11 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Definium Therapeutics Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring at full speed: most open roles are fresh.
Early Careers is the largest family, 32 of open roles.
6Posted in 30 days55% of open roles are fresh
100%Remote roles11 of 11
4Hiring offices
Can they hire you from United States?by your location
Likely
1 open roles are in your country: you apply locally, no move needed.
United States1On site
Remote, from elsewhere27Possible
No posting offers visa sponsorship. Remote roles: 27.
Time to fillmedian days to close a role
Definium Therapeutics61 days
Market, same roles39 days
Alion signals0-100
Demand12
Pay40
Your chance52
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Sep 28This week
Open roles a week: 19 then, 0 now
Where the openings areshare of open roles · trend
Early Careers32▼
Biotech20▲
Finance12▼
Analytics8
Operations8
Administrative4▲
Newest roles
Director, Tax$200k – $290k per year · Equity · Hybrid · 10+ years exp · Bachelor's Degree
Degree asked
Bachelor's Degree 75%Master's Degree 13%Doctoral Degree (PhD) 13%
Experience asked: 7.7 years on average, in 11 postings. 8 postings state a degree.
Benefits named in postingsshare of open roles
Equity11100%
Flexible time off11100%
Health insurance11100%
Flexible schedule19%
Continuous learning19%
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
What its postings pay, by level.
$220kMedian
$140k – $290kTypical rangeUSD a year
$290kHighest paying roleDirector, Tax
Source: the pay stated in the company's postings, normalised to USD a year
Footprint
Hiring in 3 cities in 1 country.
Source: office addresses in postings and company registers
Ranked #7 by open roles among its 11 closest peers.
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)
Technologies named in job postings at Definium Therapeutics over the last 12 months, by layer, with the share of postings for each.
15Technologies in use
9Postings analysed
62/100Stack modernity
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 302026
News · YahooFinance
Robert Barrow, Director, Chief Executive Officer, on September 25, 2026, sold 31,550 shares in Defin
Sep 182026
Press release · The Globe and Mail
Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.
Sep 182026
Press release · The Globe and Mail
Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.
Sep 152026
News · YahooFinance
Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets. Is the current s…
Sep 152026
News · YahooFinance
Definium Therapeutics (DFTX) just reported that its second Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met primary and key secondary endpoints, with clini…
Sources: the outlets named on each headline, each story once